Sol-Gel posts terminated Phase 2 patidegib gel trial results; 2 of 47 had serious adverse events
Sol-Gel Technologies reported results from its terminated Phase 2 study of Patidegib Topical Gel, 2% in high-frequency basal cell carcinoma patients.
- Sol-Gel Technologies posted results for its Phase 2 trial of Patidegib Topical Gel, 2% (NCT04155190) in adults with non-Gorlin high-frequency basal cell carcinoma. The study was a randomized, double blind, stratified, vehicle-controlled trial testing twice-daily application of the gel to the face over nine months.1 The trial enrolled 50 participants but was terminated early due to a low blinded event rate.1 The main goal was tracking the number of new surgically eligible basal cell carcinomas that develop on the face over the 9 month period.1 Posted safety data showed 2 of 47 participants in the overall study had serious adverse events.1
Fact check notes
- Checker's noteThe claim that Sol-Gel 'had one clinical trial update this week' is not supported by the source, which contains no information about publication timing relative to the entry's writing date.
- Sentence removed
Sol-Gel Technologies had one clinical trial update this week, with results posted for a discontinued mid-stage skin cancer study.
unsupported: Source gives no information about timing relative to 'this week'; this is an unverifiable editorial framing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.